Corvus reports initial results from Phase 1/1b trial of CPI-818
Corvus Pharmaceuticals announced initial results from its Phase 1/1b trial of CPI-818, the company's ITK-inhibitor. The early clinical data from the study demonstrated specific target engagement by CPI-818, the company said. The CPI-818 Phase 1/1b study is currently enrolling patients with several types of advanced, refractory T-cell lymphomas, including peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, cutaneous T-cell lymphoma and other T-cell lymphomas. Seven patients have been enrolled in the first two dose cohorts in the initial phase of the trial, receiving a 100 mg or 200 mg oral dose of CPI-818 two times per day, with no dose limiting toxicities and no grade 3 or 4 adverse events observed. The results from the pharmacokinetic and occupancy studies for the first seven patients have been in-line with expectations. The company anticipates that a dose that achieves maximum target occupancy will be achieved in the next one or two dose cohorts. CPI-818 has been shown to bind covalently to ITK at low nanomolar concentrations without reacting with other kinases, it added.